Lantern Pharma (NASDAQ: LTRN), an artificial intelligence-driven oncology company, announced it will host a webcast to discuss its second-quarter 2026 operating and financial results on Aug. 14, 2026, at 9 a.m. ET. President and CEO Panna Sharma, joined by members of the management team, will review results for the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials and developments involving the company’s RADR(R) and Open-Medicine AI platforms.
The announcement underscores Lantern’s strategic shift toward integrating AI across its drug development process. The company’s proprietary RADR platform leverages machine learning to analyze vast datasets and identify potential cancer therapies more efficiently. This approach is central to Lantern’s pipeline, which includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), currently being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
A key development for the company is the commercial availability of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, now offered as a subscription-based research platform for the global biomedical and drug development community. This move represents a new revenue stream for the company, diversifying its income beyond traditional drug development milestones. The platform is designed to accelerate research by integrating AI agents that can assist in hypothesis generation, experimental design, and data analysis.
The webcast will likely provide insights into how withZeta.ai is being adopted and its potential impact on the company’s financial outlook. Investors will also be keen to hear about the progress of the company’s clinical trials, particularly the HARMONIC trial, which is a critical test for LP-300 in a specific patient population. Additionally, updates on LP-184’s development for pediatric CNS cancers through Starlight Therapeutics could signal near-term catalysts.
Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s focus on AI-driven drug discovery is part of a broader industry trend toward precision medicine, where treatments are tailored to individual genetic profiles. By leveraging AI, Lantern aims to reduce the time and cost associated with traditional drug development, potentially bringing new therapies to market faster.
The webcast replay will be available through the investor relations section of Lantern Pharma’s website following the event. For more information, visit the full press release at https://ibn.fm/l80kv. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
